Syndrome News and Research

RSS

Could type III interferons be used as a SARS-CoV-2 therapeutic?

Researchers have found that both type I and type III interferons can inhibit SARS-CoV-2 infection in human intestinal cells, but type III interferons can act faster and for a longer period, making them suitable for potential therapeutics.

17 Jun 2021

Could wastewater epidemiology help track the circulation of SARS-CoV-2 variants?

In a new study, released as a preprint on the medRxiv* server, researchers from Germany, Italy and Netherlands demonstrated the utility of integrating genomic and wastewater based epidemiology (WBE) to provide unprecedented insight into the abundance of SARS-CoV-2 and the profile of the mutations associated with the VOCs (i.e., B.1.1.7, B.1.351, P.1, and B.1.617.2) in the wastewater samples.

17 Jun 2021

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.

17 Jun 2021

AI ECG as a novel noninvasive approach to diagnosing cardiac injury in COVID-19 patients

A recent study discusses the efficacy of an AI-enhanced ECG technique that has been used to diagnose left ventricular dysfunction in COVID-19 patients.

17 Jun 2021

How the common cold can provide protection against COVID-19

In a recent study, researchers found that prior infection with the rhinovirus can provide a more effective immune response against SARS-CoV-2 infection.

17 Jun 2021

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Researchers in the United States have demonstrated the effectiveness of early treatment with REGEN-COV™ at preventing symptomatic disease among people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Jun 2021

Full vaccination prevents emergency care and hospitalization in cases of breakthrough COVID-19

Researchers in the United States have demonstrated the effectiveness of the Pfizer-BioNTech, Moderna, and Johnson & Johnson coronavirus disease 2019 (COVID-19) vaccines at reducing the need for emergency care or hospitalization following breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Jun 2021

Immune system dysfunction can alter the link between cannabis use and psychosis

The presence of pro-inflammatory cytokines in the blood can boost the effects of daily cannabis use and heighten the risk of developing psychosis in adulthood.

16 Jun 2021

A comprehensive review on diagnostics of COVID-19

Clinical research on COVID-19 has boomed in the 18 months since the disease first appeared. Countless papers have looked at the topic from almost every possible angle, including methods of detection.

16 Jun 2021

Corticosteroids may effectively treat children who develop a serious disorder after COVID-19

Corticosteroids may be an effective treatment for children who develop a rare but serious condition after COVID-19 infection.

16 Jun 2021

'Wonder material' used to detect SARS-CoV-2 virus in laboratory experiments

Researchers at the University of Illinois Chicago have successfully used graphene -- one of the strongest, thinnest known materials -- to detect the SARS-CoV-2 virus in laboratory experiments.

16 Jun 2021

Scientists reveal the mechanism of liquid-liquid phase separation of SARS-CoV-2 nucleocapsid

A team of scientists from the United States has recently revealed how interactions between the SARS-CoV-2 nucleocapsid protein and the double-stranded RNA motifs impart distinct droplet properties that can support multiple viral functions. The study is currently available on the bioRxiv* preprint server.

16 Jun 2021

Reducing coronavirus-related mortality through senolytics

A study recently published in the journal Science explores the concept of senescent cells (SnC) having a hyperinflammatory response and the use of a class of small molecules called senolytics to combat this.

16 Jun 2021

Could daily rapid testing replace mandatory quarantine to prevent imported SARS-CoV-2 infections?

A new study, released as a preprint on the medRxiv* server, examines the relative effectiveness of varying strategies, such as pre-flight testing, longer or shorter periods of quarantine, tests for release, or daily testing after the flight, using modeling tools. The results show that it is feasible to avoid quarantine by the use of lateral flow testing daily for five days, achieving higher reductions in the number of secondary cases caused by an infected traveler in the country of destination.

16 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

A new paper in the journal Nature offers a reassuring answer, showing that convalescent COVID-19 patients, some of whom had received vaccination as well, retain antiviral antibodies and neutralizing activity, as well as memory B cells, for up to 6-12 months from infection.

16 Jun 2021

Increased viral replication and shedding in nonhuman primates carrying SARS-CoV-2 B.1.1.7 variant

A team of researchers from the US and UK used the AGM intranasal model of SARS-CoV-2 infection to determine differences between a contemporary SARS-CoV-2 D614G variant circulating in summer 2020 and the B.1.1.7 UK variant of concern that emerged in late 2020.

16 Jun 2021

Cissampelos pareira (velvetleaf) exhibits anti-SARS-CoV-2 potential

Cissampelos pareira (Cipa), also known as velvetleaf, is a widely used hormone modulator used to treat reproductive disorders and fever. Research has shown that it can inhibit three serotypes of Dengue virus (DENV) and affect various hormones.

16 Jun 2021

Prior vaccination against diphtheria and tetanus associated with less severe COVID-19

The researchers found that individuals with registered diphtheria or tetanus vaccinations were less likely to develop severe COVID-19 than people who had only received other vaccinations. The results of this study are posted to the medRxiv* preprint server.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

Syndrome News and Research

Could type III interferons be used as a SARS-CoV-2 therapeutic?

Could wastewater epidemiology help track the circulation of SARS-CoV-2 variants?

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

AI ECG as a novel noninvasive approach to diagnosing cardiac injury in COVID-19 patients

How the common cold can provide protection against COVID-19

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Full vaccination prevents emergency care and hospitalization in cases of breakthrough COVID-19

Immune system dysfunction can alter the link between cannabis use and psychosis

A comprehensive review on diagnostics of COVID-19

Corticosteroids may effectively treat children who develop a serious disorder after COVID-19

'Wonder material' used to detect SARS-CoV-2 virus in laboratory experiments

Scientists reveal the mechanism of liquid-liquid phase separation of SARS-CoV-2 nucleocapsid

Reducing coronavirus-related mortality through senolytics

Could daily rapid testing replace mandatory quarantine to prevent imported SARS-CoV-2 infections?

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

Increased viral replication and shedding in nonhuman primates carrying SARS-CoV-2 B.1.1.7 variant

Cissampelos pareira (velvetleaf) exhibits anti-SARS-CoV-2 potential

Prior vaccination against diphtheria and tetanus associated with less severe COVID-19

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News